Neuroendocrine prostate cancer (NEPC) is a sub-variant of aggressive prostate cancer that rarely arises de novo, but most frequently emerges after androgen receptor (AR)-targeted therapies for prostate adenocarcinoma (1). The gene discussed is AR; the disease is prostate cancer.